9th Circ. Puts Lid On Actimmune Marketing Action
The Ninth Circuit on Friday upheld the dismissal of a proposed class action claiming biotechnology company InterMune Inc. fraudulently promoted its drug Actimmune as a remedy for a deadly lung disease...To view the full article, register now.
Already a subscriber? Click here to view full article